Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Phase 2

Completed

Conditions: Adult Type Ovarian Granulosa Cell Tumor
Ovarian Gynandroblastoma
Ovarian Sex Cord Tumor With Annular Tubules
Ovarian Sertoli-Leydig Cell Tumor
Ovarian Steroid Cell Tumor

Interventions: Drug: Paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2020-03-05

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 31

Registration Number: NCT00006227

Locations: 🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 95 locations

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005051

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Saint Vincent Catholic Medical Center of New York, New York, New York, United States
🇺🇸
New York Hospital Medical Center of Queens, Fresh Meadows, New York, United States

and more 7 locations

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-19

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00009880

Locations: 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Mount Carmel West Hospital, Columbus, Ohio, United States

and more 63 locations

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: estramustine
Drug: etoposide
Drug: flutamide
Drug: goserelin
Drug: leuprolide
Drug: nilutamide
Drug: paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 41

Registration Number: NCT00028769

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 88 locations

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-10

Lead Sponsor: Tulane University Health Sciences Center

Registration Number: NCT00028860

Locations: 🇺🇸
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

Phase 3

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 166

Registration Number: NCT00003128

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Tufts - New England Medical Center, Boston, Massachusetts, United States

and more 14 locations

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Phase 1

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003342

Locations: 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States